News Conference News SCCT 2017 Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See? Yael L. Maxwell July 10, 2017
News Daily News Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete? Michael O'Riordan June 05, 2017
News Daily News Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI L.A. McKeown May 23, 2017
News Daily News $2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor Michael O'Riordan May 12, 2017
News Daily News Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women Todd Neale May 11, 2017
News Daily News More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds Todd Neale May 05, 2017
News Daily News Drugs Most Heavily Promoted by Pharma Don’t Necessarily Offer the Best Health Value Todd Neale May 04, 2017
News Daily News ‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum Todd Neale April 27, 2017
News Conference News EAS 2017 FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data Yael L. Maxwell April 26, 2017
News Daily News One in Five Acute MI Patients Drop Statins Within 2 Years Michael O'Riordan April 20, 2017
News Daily News If You Don’t Take Your Stroke Meds, This App Will Tell on You Todd Neale April 18, 2017
News Daily News Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows Michael O'Riordan March 31, 2017
News Conference News ACC 2017 Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them Yael L. Maxwell March 23, 2017
News Conference News ACC 2017 CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS Yael L. Maxwell March 18, 2017
News Conference News ACC 2017 Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe Todd Neale March 18, 2017
News Conference News ACC 2017 SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab Yael L. Maxwell March 17, 2017
News Conference News ACC 2017 FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo Michael O'Riordan March 17, 2017
News Daily News NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease Todd Neale March 14, 2017
News Conference News ACC 2017 Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term Michael O'Riordan March 10, 2017